Study Design
This phase 1, single-dose, open-label, three-arm study was conducted at a single center in the USA between October 12, 2021, and April 12, 2022 (NCT05059977). The study consisted of a screening period of up to 21 days before fSCIG 20% dosing, a 4-day study treatment period, and a follow-up period of up to 12 (± 1) weeks after a single fSCIG 20% infusion (Fig. Overall study design 